Ovid Therapeutics, Inc.
http://www.ovidrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ovid Therapeutics, Inc.
Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives
Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.
Takeda’s Soticlestat Fails In Seizure Trials
Two Phase III studies testing soticlestat, licensed from Ovid, in Dravet and Lennox-Gastaut syndromes failed to meet their primary endpoints on improvement in seizure frequency.
Stoke’s Persistence Pays Off With Dravet Syndrome Therapy
Results showing a 74% reduction in seizures set up Stoke for a pivotal study and could make STK-001 the first disease-modifying agent for the condition.
Takeda Charges Into Diversification With ITP Win
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice